Retatrutide, a novel dual activator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising results in early human studies. Recent examination indicates that retatrutide may offer substantial benefits for people with type , particularly regarding weight decrease and glucose regulation. Further investi